Clinical trials: Semaglutide
Diabetes Mellitus, Type 2
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
This study compares the medicines semaglutide and empagliflozin in people with newly diagnosed type 2 diabetes and obesity. The study will look mainly at how well the blood sugar and body weight are controlled when participants…
- Trial name
- PIONEER START (NCT05444153)
- Testing
- Semaglutide, Empagliflozin
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
This is a 32-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and the active comparator in patients with type 2 diabetes…
- Trial name
- NCT06739044
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity, Overweight
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable…
- Trial name
- NCT06584916
- Testing
- Orforglipron
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Eli Lilly and Company
Facial Skin Aging, Facial Volume Loss
Comparing Facial Aging Between Identical Twins With 3D Imaging
Identical twins share the same genes, which makes them a powerful way to study how lifestyle and environment - rather than genetics - affect how faces age.
- Conditions
- Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
- Trial name
- NCT07760532
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ponsky Facial Aesthetics And Plastic Surgery, Llc
Obesity, Type 2 Diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight.
- Trial name
- NCT07564414
- Testing
- Cagrisema, Semaglutide
- Where
- 303 sites in United States, Argentina and 17 more
- Volunteers
- 2,500 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers, Type 2 Diabetes
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested. One is the current formulation and the other one is a new formulation of semaglutide.
- Trial name
- NCT04097600
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes.
- Trial name
- NCT05144984
- Testing
- NNC0480-0389, Semaglutide
- Where
- 129 sites in United States, Bulgaria and 7 more
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers Type 2 Diabetes
A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
The goal of this trial is to find out whether taking semaglutide tablets at different times before and after eating has a similar effect compared to the recommended dosing time.
- Trial name
- NCT04513704
- Testing
- Oral Semaglutide
- Where
- United Kingdom
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with type 2 diabetes (T2D). People taking part in the study will take the medicine together with their current diabetes medicine…
- Trial name
- SUSTAIN FORTE (NCT03989232)
- Testing
- Semaglutide
- Where
- 129 sites in United States, Bulgaria and 9 more
- Volunteers
- 961 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Peripheral Arterial Disease
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes.
- Trial name
- STRIDE (NCT04560998)
- Testing
- Semaglutide
- Where
- 283 sites in United States, Austria and 19 more
- Volunteers
- 792 people
- Sponsor
- Novo Nordisk A/S
Pharmacokinetics, Safety Issues
Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.
Study of comparative pharmacokinetics and biosimilarity of drugs containing semaglutide - GP40221 and Ozempic® in healthy volunteers.
- Conditions
- Pharmacokinetics, Safety Issues, Bioequivalence
- Trial name
- NCT06497049
- Testing
- GP40221, ozempic
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Geropharm
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.
- Trial name
- PIONEER 5 (NCT02827708)
- Testing
- semaglutide
- Where
- 117 sites in United States, Denmark and 6 more
- Volunteers
- 324 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04537624)
- Testing
- Oral Semaglutide
- Where
- Switzerland
- Volunteers
- 194 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D).
- Trial name
- NCT05478252
- Testing
- Semaglutide J, Semaglutide B
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 388 people
- Sponsor
- Novo Nordisk A/S
Muscle Wasting, Obesity & Overweight
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
The goal of this clinical trial is to learn if BIO101 treatment can improve the muscle strength of participants males and females, aged 18 to 84 years old, suffering from obesity (BMI≥30) or overweight (BMI ≥ 27) with one or more…
- Conditions
- Muscle Wasting, Obesity & Overweight, Obesity
- Trial name
- OBA (NCT07411378)
- Testing
- BIO101, Semaglutide
- Volunteers
- 164 people
- Sponsor
- Biophytis
Healthy Participants
A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants
In this study, a known medicine called 'semaglutide' will be tested in a new tablet version. The medicine will be tested in healthy men to explore the effect of different water volumes and tablet-meal delays on blood levels of…
- Trial name
- NCT05996874
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).
- Trial name
- SUSTAIN™1 (NCT02054897)
- Testing
- semaglutide
- Where
- 86 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic control after metformin treatment.
- Trial name
- NCT06339086
- Testing
- Semaglutide Injection, Semaglutide Injection(Ozempic®), Metformin
- Volunteers
- 478 people
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
Type 2 Diabetes (T2DM)
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes.
- Trial name
- NCT07046273
- Testing
- F027, Ozempic®
- Volunteers
- 496 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Diabetes Mellitus, Type 2
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions.
- Trial name
- NCT05714683
- Testing
- Semaglutide
- Volunteers
- 600 people
- Sponsor
- Novo Nordisk A/S